Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody designed to specifically target HER3. This antibody effectively inhibits the activation of members of the epidermal growth factor receptor (ErbB) family and their downstream signaling pathways. Seribantumab has demonstrated the ability to suppress neuregulin 1 (NRG1) fusion-dependent tumorigenesis both in vitro and in vivo, showing efficacy in patient-derived models of breast, lung, and ovarian cancers. This makes it a valuable tool for research in cancer biology, particularly in studies focusing on the molecular mechanisms of tumorigenesis and therapeutic antibody development.
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody designed to specifically target HER3. This antibody effectively inhibits the activation of members of the epidermal growth factor receptor (ErbB) family and their downstream signaling pathways. Seribantumab has demonstrated the ability to suppress neuregulin 1 (NRG1) fusion-dependent tumorigenesis both in vitro and in vivo, showing efficacy in patient-derived models of breast, lung, and ovarian cancers. This makes it a valuable tool for research in cancer biology, particularly in studies focusing on the molecular mechanisms of tumorigenesis and therapeutic antibody development.
Product Information
Catalog Num
AT0264
Molecular Weight
143140
CAS Number
1334296-12-6
Isotype
Human IgG2 kappa, Isotype Control
Species
Human
Synonyms
SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
